Literature DB >> 2109631

Long-term toxicity of chemotherapy for testicular cancer--the cost of cure.

N S Stuart1, C M Woodroffe, R Grundy, M H Cullen.   

Abstract

Twenty-seven patients cured of advanced testicular cancer by cisplatin-based chemotherapy have been assessed, a median of 30 months after start of treatment, for the long-term effects of such treatment on renal, endocrine, audiometric, reproductive and respiratory function. To control for the effects of orchidectomy on endocrine function a similar group of 11 patients cured by orchidectomy alone was also assessed. The extents of impairment in hearing and renal function were related to the total dose of cisplatin received, while the majority of patients had respiratory impairment which was, in part, related to the total dose of bleomycin. TSH was significantly higher in the chemotherapy group although serum free thyroxine and free T3 were normal in all. FSH was raised in 67% of the chemotherapy group although serum free thyroxine and free T3 were while LH was raised in 75% and 45% respectively. Serum testosterone was normal in all. The levels of FSH and LH were both independently correlated with age of the patient while FSH was higher in patients having more chemotherapy and had a tendency to fall towards normal with time since treatment. Over half the patients had normal sperm concentrations although 74% had a raised proportion of abnormal sperm. Indices of sperm function were worse in patients having more chemotherapy but sperm number increased towards normal with time since treatment, particularly after the second year. The long-term side-effects of chemotherapy for testicular cancer are thus generally mild but are largely irreversible and their severity is related to the total amount of chemotherapy received. As their longer term significance is not clear we would recommend that, in the treatment of testicular cancer, doses of chemotherapy are reduced to the minimum required for cure. Assessment of long-term side-effects of chemotherapy for testicular cancer should be a mandatory part of any study of such treatment and should be considered in any comparison of different therapies.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2109631      PMCID: PMC1971302          DOI: 10.1038/bjc.1990.106

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

1.  Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients.

Authors:  A Yagoda; B Mukherji; C Young; E Etcubanas; C Lamonte; J R Smith; C T Tan; I H Krakoff
Journal:  Ann Intern Med       Date:  1972-12       Impact factor: 25.391

2.  Serum hormone levels in patients with malignant testicular germ cell tumours without clinical and/or radiological signs of tumour.

Authors:  S D Fosså; O Klepp; A Aakvaag
Journal:  Br J Urol       Date:  1980-04

3.  Testicular cancer in England and Wales: some epidemiological aspects.

Authors:  J M Davies
Journal:  Lancet       Date:  1981-04-25       Impact factor: 79.321

4.  cis-Platinum ototoxicity.

Authors:  L Helson; E Okonkwo; L Anton; E Cvitkovic
Journal:  Clin Toxicol       Date:  1978       Impact factor: 4.467

5.  Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients.

Authors:  N V Aguilar-Markulis; S Beckley; R Priore; C Mettlin
Journal:  J Surg Oncol       Date:  1981       Impact factor: 3.454

6.  Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration.

Authors:  R R Reddel; R F Kefford; J M Grant; A S Coates; R M Fox; M H Tattersall
Journal:  Cancer Treat Rep       Date:  1982-01

7.  Role of pulmonary function tests in the prevention of bleomycin pulmonary toxicity during chemotherapy for metastatic testicular teratoma.

Authors:  H H Lucraft; P M Wilkinson; T B Stretton; G Read
Journal:  Eur J Cancer Clin Oncol       Date:  1982-02

8.  Routine pulmonary function tests during bleomycin therapy. Tests may be ineffective and potentially misleading.

Authors:  B M Lewis; R Izbicki
Journal:  JAMA       Date:  1980-01-25       Impact factor: 56.272

9.  Chemotherapy of disseminated testicular cancer. A random prospective study.

Authors:  L H Einhorn; S D Williams
Journal:  Cancer       Date:  1980-09-15       Impact factor: 6.860

10.  Chemotherapy of advanced malignant teratomas.

Authors:  E S Newlands; R H Begent; S B Kaye; G J Rustin; K D Bagshawe
Journal:  Br J Cancer       Date:  1980-09       Impact factor: 7.640

View more
  13 in total

Review 1.  Comparative tolerability of chemotherapy regimens for germ cell cancer.

Authors:  S Culine; J P Droz
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

2.  Successful pregnancy outcome using sperm from severely diseased men with testicular cancer and collagen disease: Three case reports.

Authors:  Sachiko Sasaki; Keiko Sasaki; Sayaka Takahashi; Toshie Sasaki; Koichi Kyono; Yasuhisa Araki
Journal:  Reprod Med Biol       Date:  2004-05-20

3.  Thyroid function and thyroid autoimmunity in childhood acute lymphoblastic leukemia off-therapy patients treated only with chemotherapy.

Authors:  M Delvecchio; V Cecinati; L P Brescia; M F Faienza; D De Mattia; L Cavallo; N Santoro
Journal:  J Endocrinol Invest       Date:  2009-07-28       Impact factor: 4.256

4.  Exploring the spectrum of late effects following radical orchidectomy for stage I testicular seminoma: a systematic review of the literature.

Authors:  Jennifer A Soon; Angelyn Anton; Javier Torres; Ruth Lawrence; Phillip Parente; Joseph McKendrick; Ian D Davis; Carmel Pezaro
Journal:  Support Care Cancer       Date:  2018-10-22       Impact factor: 3.603

5.  Early manifestation of mild cognitive impairment in B-cell non-Hodgkin's lymphoma patients receiving CHOP and rituximab-CHOP chemotherapy.

Authors:  Mohd Ashif Khan; Kamlesh Garg; Dinesh Bhurani; Nidhi Bharal Agarwal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-08-27       Impact factor: 3.000

Review 6.  Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.

Authors:  Francesco Torino; Salvatore Maria Corsello; Raffaele Longo; Agnese Barnabei; Giampietro Gasparini
Journal:  Nat Rev Clin Oncol       Date:  2009-04       Impact factor: 66.675

7.  Hypogonadism in male cancer patients.

Authors:  Basil O Burney; Jose M Garcia
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-04-20       Impact factor: 12.910

8.  Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.

Authors:  C Bokemeyer; C C Berger; J T Hartmann; C Kollmannsberger; H J Schmoll; M A Kuczyk; L Kanz
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

9.  Fertility, gonadal and sexual function in survivors of testicular cancer.

Authors:  R A Huddart; A Norman; C Moynihan; A Horwich; C Parker; E Nicholls; D P Dearnaley
Journal:  Br J Cancer       Date:  2005-07-25       Impact factor: 7.640

10.  Thyroid abnormalities in survivors of childhood cancer.

Authors:  Ayla Akca Çağlar; Aynur Oğuz; Faruk Güçlü Pınarlı; Ceyda Karadeniz; Arzu Okur; Aysun Bideci; Ülker Koçak; Hüseyin Bora
Journal:  J Clin Res Pediatr Endocrinol       Date:  2014-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.